Search results
Showing 121 to 135 of 155 results for medicines optimisation
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
decisions about surgery. Preoperative optimisation clinics for older people Preoperative optimisation clinics for older...
decisions about surgery. Preoperative optimisation clinics for older people Preoperative optimisation clinics for older...
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD such as anxiety, sleep problems and difficulties with concentration. Recommendations also aim to raise awareness of the condition and improve coordination of care.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults.
Pelvic floor dysfunction: prevention and non-surgical management (NG210)
This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
frequently using unscheduled care, people prescribed multiple regular medicines, and people who are housebound or care home...
This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.